Your browser doesn't support javascript.
loading
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.
Zhang, Tian; Pabla, Sarabjot; Lenzo, Felicia L; Conroy, Jeffrey M; Nesline, Mary K; Glenn, Sean T; Papanicolau-Sengos, Antonios; Burgher, Blake; Giamo, Vincent; Andreas, Jonathan; Wang, Yirong; Bshara, Wiam; Madden, Katherine G; Shirai, Keisuke; Dragnev, Konstantin; Tafe, Laura J; Gupta, Rajan; Zhu, Jason; Labriola, Matthew; McCall, Shannon; George, Daniel J; Ghatalia, Pooja; Dayyani, Farshid; Edwards, Robert; Park, Michelle S; Singh, Rajbir; Jacob, Robin; George, Saby; Xu, Bo; Zibelman, Matthew; Kurzrock, Razelle; Morrison, Carl.
Afiliación
  • Zhang T; Department of Medicine, Duke University, Durham, NC, USA.
  • Pabla S; R&D, OmniSeq, Inc, Buffalo, NY, USA.
  • Lenzo FL; R&D, OmniSeq, Inc, Buffalo, NY, USA.
  • Conroy JM; R&D, OmniSeq, Inc, Buffalo, NY, USA.
  • Nesline MK; Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Glenn ST; R&D, OmniSeq, Inc, Buffalo, NY, USA.
  • Papanicolau-Sengos A; R&D, OmniSeq, Inc, Buffalo, NY, USA.
  • Burgher B; Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Giamo V; R&D, OmniSeq, Inc, Buffalo, NY, USA.
  • Andreas J; R&D, OmniSeq, Inc, Buffalo, NY, USA.
  • Wang Y; R&D, OmniSeq, Inc, Buffalo, NY, USA.
  • Bshara W; R&D, OmniSeq, Inc, Buffalo, NY, USA.
  • Madden KG; R&D, OmniSeq, Inc, Buffalo, NY, USA.
  • Shirai K; R&D, OmniSeq, Inc, Buffalo, NY, USA.
  • Dragnev K; Department of Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
  • Tafe LJ; Department of Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
  • Gupta R; Department of Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
  • Zhu J; Department of Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
  • Labriola M; Department of Medicine, Duke University, Durham, NC, USA.
  • McCall S; Department of Medicine, Duke University, Durham, NC, USA.
  • George DJ; Department of Medicine, Duke University, Durham, NC, USA.
  • Ghatalia P; Department of Medicine, Duke University, Durham, NC, USA.
  • Dayyani F; Department of Medicine, Duke University, Durham, NC, USA.
  • Edwards R; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, US.
  • Park MS; Department of Medicine, University of California, Irvine, CA, USA.
  • Singh R; Department of Medicine, University of California, Irvine, CA, USA.
  • Jacob R; Department of Medicine, University of California, Irvine, CA, USA.
  • George S; Department of Medicine, Meharry Medical College, Nashville, TN, US.
  • Xu B; Department of Medicine, Meharry Medical College, Nashville, TN, US.
  • Zibelman M; Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Kurzrock R; Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Morrison C; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, US.
Oncoimmunology ; 9(1): 1773200, 2020 06 10.
Article en En | MEDLINE | ID: mdl-32923131

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Oncoimmunology Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Antineoplásicos Inmunológicos Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Oncoimmunology Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos